<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309501</url>
  </required_header>
  <id_info>
    <org_study_id>TLQT Plaster</org_study_id>
    <nct_id>NCT03309501</nct_id>
  </id_info>
  <brief_title>Tong-Luo-Qu-Tong Plaster for KOA: a Randomised, Double-blind, Parallel Positive Control, Multi-center Clinical Trial</brief_title>
  <official_title>Study on Efficacy, Safety and Economy of Tong-Luo-Qu-Tong Plaster Treatment for Knee Osteoarthritis: Study Protocol for a Randomised, Double-blind, Parallel Positive Control, Multi-center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhongnan Hospital Affiliated to Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Suzhou Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luoyang Osteopathy hospital of Henan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth Central Hospital of Tianjin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knee osteoarthritis(OA), also known as degenerative arthritis, have affected a lot of people.&#xD;
      Patients with severe osteoarthritis frequently develop one or more of the typically following&#xD;
      symptoms: joint pain, stiffness, activity with joint friction noise, limited mobility, such&#xD;
      as difficulty walking and climbing. Now there are many western medicine treatments including&#xD;
      symptom relief and joint cartilage protective agents for OA, but the results have not yet&#xD;
      satisfied. TCM treatment of osteoarthritis has remarkable curative effect and unique&#xD;
      advantage.Tong-Luo-Qu-Tong Plaster is a common method to treat osteoarthritis of the knee for&#xD;
      thousands of years in China. It lacked a large sample randomised, double-blind, parallel&#xD;
      positive controlled, multicenter clinical trial, and the clinical evidence of&#xD;
      Tong-Luo-Qu-Tong Plaster for Knee Osteoarthritis need to be further completed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, parallel positive controlled, multicenter clinical trial will be&#xD;
      conducted to assess the effectiveness and safety of Tong-Luo-Qu-Tong Plaster on patients with&#xD;
      knee osteoarthritis. A total of 2000 patients with knee osteoarthritis will be recruited and&#xD;
      randomly allocated into experimental group(1500) or control group(500). Each patient will&#xD;
      undergo a 2-week treatment with herbal patches for one session per day.The western Ontario&#xD;
      and McMaster universities osteoarthritis index (WOMAC) as objective indicators of efficacy is&#xD;
      the primary efficacy endpoint of the study.The secondary outcome measures are the changes in&#xD;
      TCM syndrome quantitative score, Visual Analog Scale/Score (VAS) score of pain, and the&#xD;
      effective time of pain relief of drug from the baseline to 1 week, 2 weeks' follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">September 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>positive control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC scores</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
    <description>Western Ontario and McMaster universities osteoarthritis index, ranges 0-96. Higher values represent a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TCM syndrome quantitative scores</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
    <description>Referring to the Guidelines on the clinical research of Chinese medicine new drugs(2002), the TCM syndrome quantitative score ranges 0-21.Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue pain scale</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
    <description>Visual Analog Scale /Score ranges 0-10.Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On effective time of pain relief of drug</measure>
    <time_frame>In 2 weeks</time_frame>
    <description>The effective time of pain relief was the time of 10mm was reduced for the first time according to the daily VAS score of the patient's diary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Chronic Musculoskeletal Disease</condition>
  <arm_group>
    <arm_group_label>Tong-Luo-Qu-Tong Plaster group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Qi-Zheng-Xiao-Tong Plaster group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tong-Luo-Qu-Tong Plaster</intervention_name>
    <description>for 14 days as two period of treatment, daily 1 time.</description>
    <arm_group_label>Tong-Luo-Qu-Tong Plaster group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qi-Zheng-Xiao-Tong Plaster</intervention_name>
    <description>for 14 days as two period of treatment, daily 1 time</description>
    <arm_group_label>Qi-Zheng-Xiao-Tong Plaster group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who have symptomatic knee osteoarthritis, diagnosis of KOA was based on&#xD;
             criteria developed by the American College of Rheumatology(ACR) in 1986&#xD;
&#xD;
          -  The differentiation standard of the arthralgia syndrome of traditional Chinese&#xD;
             medicine(TCM): Referring to the Guidelines on the clinical research of Chinese&#xD;
             medicine new drugs(2002)&#xD;
&#xD;
          -  The visual analog scale score is no less than 30 mm.&#xD;
&#xD;
          -  The patient is older than or equal to 40 years old&#xD;
&#xD;
          -  All the patients signed informed consent form before study begins&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hormone therapy was used in the first month of screening&#xD;
&#xD;
          -  Arthroscopy and intra-articular injection was performed on the knee joint which is&#xD;
             going to be evalued during the first three months of screening.&#xD;
&#xD;
          -  There is a history of trauma or surgery in the knee joint six months before screening&#xD;
             or participants who a history of lessmore than three trauma or surgical procedures in&#xD;
             the knees&#xD;
&#xD;
          -  Participants who have knee arthroplasty, lumbar spinal stenosis, ankylosing&#xD;
             spondylitis, rheumatic arthritis, rheumatoid factor positive(&gt;40), eallergic&#xD;
             constitution and mental disorder will be excluded from the trial&#xD;
&#xD;
          -  Patients has severe diseases and complications such as severe diabetes, serious liver&#xD;
             and kidney disease, malignant tumors, infectious diseases or complications affecting&#xD;
             the knee joints&#xD;
&#xD;
          -  Pregnant,lactating women&#xD;
&#xD;
          -  Subjects are participating in or have participated in other clinical trials in the&#xD;
             first three months.&#xD;
&#xD;
          -  Subjects cannot stop using the drugs immediately with a long-term use of other related&#xD;
             drugs.&#xD;
&#xD;
          -  Combined with severe primary diseases such as hepatic renal functionand hematopoietic&#xD;
             system, such as liver function (ALT≧1.5×ULN), and kidney function(AST≧1.5×ULN)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongjun Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Longhua Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuejun Cui, Doctor</last_name>
    <phone>021-64385700</phone>
    <phone_ext>1309</phone_ext>
    <email>13917715524@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Longhua Hospital, Shanghai University of TCM</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuejun Cui, Dr</last_name>
      <phone>021-64385700</phone>
      <phone_ext>1309</phone_ext>
      <email>13917715524@139.com</email>
    </contact>
    <investigator>
      <last_name>Yongjun Wang, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Cui xuejun</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Knee osteoarthritis</keyword>
  <keyword>Randomised Double-blind Controlled trial</keyword>
  <keyword>Tong-Luo-Qu-Tong Plaster</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

